The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited therapy may be feasible in certain cases, particularly when combined with other targeted agents.
Inhye E. Ahn, MD
Inhye E. Ahn, MD, is an assistant professor of medicine at the Dana-Farber Cancer Institute in Boston, MA.
Articles by Inhye E. Ahn, MD
Latest Updated Articles
BTK Inhibitor Therapy Can Be Stopped in CLLPublished: September 20th 2024 | Updated: